Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolios

Merck To Acquire Brazilian Animal Health Company For $400M

Published 07/04/2016, 11:28 PM
Updated 07/09/2023, 06:31 AM
MRK
-
UTHR
-
ANIP
-
GWPH
-

Merck & Co. Inc. (NYSE:MRK) announced that it will acquire the controlling interest in Vallée S.A., a Brazil-based privately held producer of animal health products.

Under the terms, Merck’s animal health business will acquire 93% of Vallée’s shares for $400 million, based on current exchange rates. The transaction is subject to regulatory review and closing conditions. However, Merck has not announced a closing date for the deal.

Benefits for Merck’s Animal Health

Under this deal, Vallée’s extensive product portfolio, consisting of over 100 products across parasiticides, anti-infectives and vaccines, for livestock, horses, and companion animals, will be integrated with Merck’s animal-health segment.

The acquisition will strengthen Merck’s presence in Latin America and help to respond more quickly and effectively to the region’s needs. Latin America, which contributes 11% to the world food production, is an important driver of the agriculture industry. A significant number of cattle across the region are vaccinated using Vallée’s products.

We note that Merck has been pursuing strategic acquisitions to boost its animal health. In Nov 2015, the company had acquired Harrisvaccines, Inc., a privately held company that develops, manufactures and sells vaccines for food production and companion animals.

Merck currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include GW Pharmaceuticals plc (NASDAQ:GWPH) , ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) and United Therapeutics Corporation (NASDAQ:UTHR) . Each of these stocks sports a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

MERCK & CO INC (MRK): Free Stock Analysis Report

UTD THERAPEUTIC (UTHR): Free Stock Analysis Report

GW PHARMA-ADR (GWPH): Free Stock Analysis Report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

Original post

Zacks Investment Research

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.